Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | TPH1 | P17752 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26268452 | 0.84 | ALOX5 (0.34) | ALOX5ALDH1A1TSHRMAPTHPGD | |
| SCHEMBL4854034 | 0.82 | ALOX5 (0.42) | ALOX5ALDH1A1TSHRMAPTHPGD | |
| SCHEMBL14868618 | 0.76 | KMT2A (0.47) | ALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL24433742 | 0.75 | TPH1 (0.31) | TPH1 | |
| SCHEMBL24433716 | 0.75 | TPH1 (0.31) | TPH1 | |
| SCHEMBL14868662 | 0.73 | FAAH (0.36) | ALOX5ALDH1A1TSHRMAPTHPGD | |
| SCHEMBL14868709 | 0.73 | PRMT6 (0.44) | ALDH1A1MAPTNPC1POLBTDP1 | |
| SCHEMBL14868655 | 0.73 | CHRM2 (0.39) | ALOX5ALDH1A1MAPTNPC1CYP2C19 | |
| SCHEMBL14868467 | 0.72 | TPH1 (0.35) | TSHRTPH1 | |
| SCHEMBL14868322 | 0.72 | GRIN2D (0.46) | ALDH1A1TSHRMAPTHPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | ALOX5 2462/4885ALDH1A1 980/4885TSHR 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.